Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

Lipid-Lowering Drug Use Rising in PI-Treated HIV Patients




 

AIDS Weekly (09.29.03) - Friday, October 17, 2003

Use of lipid-lowering therapy (LLT) is rising among HIV patients on antiretroviral therapy, despite limited evidence of their benefits in this population, a recent study noted. Many patients receiving protease inhibitors (PIs) develop hyperlipidemia, which may increase the risk of future coronary events, study author J. H. Stein and colleagues at the University of Wisconsin explained.

The researchers conducted a cross-sectional study of HIV- positive adults registered in the Medicaid of California (MEDI- CAL) database to estimate "the changing prevalence of lipid- lowering therapy (LLT) in patients with HIV, and to evaluate its association with the use of HIV PIs" from January 1996 to June 2002. The scientists found that in patients taking PIs for HIV, LLT prevalence increased more than sixfold, at a faster rate than for HIV patients not on PIs as well as for patients in the general population. This occurred despite the fact that "it has not been proved that use of LLT in HIV-infected patients taking PIs improves survival," the study said.

The report, "Increased Use of Lipid-Lowering Therapy in Patients Receiving Human Immunodeficiency Virus Protease Inhibitors," appeared in the American Journal of Cardiology (2003;92(3):270-274).



 


Copyright © 2003 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in October 17, 2003. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.